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Donor-related autoimmune diseases after hematopoietic cell
transplantation (HCT) are not well characterized. Most post-
transplant immune disorders come in the guise of GVHD or
reactions by the recipient to therapy (pneumonitis). The
extreme minority are due to donor-related adoptive immu-
nity. It is interesting that donor-derived auto-immune issues
are not more common after HCT, suggesting the presence of
identiﬁable risk factors.
A 30-year-old male underwent myeloablative matched
related allogeneic peripheral blood stem cell transplant for
Philadelphia chromosome positive Acute Lymphoid Leuke-
mia (ALL). Importantly, the patient did not have any history
of rheumatologic disorders, and speciﬁcally no history of
Systemic Lupus Erythematosus (SLE). On D+10 he developed
chest pain; echocardiogram showed a moderate pericardial
effusion that resolved with NSAIDs therapy. He later (D+73)
developed myalgia and poly-synovitis requiring signiﬁcant
doses of opioids for relief. Infectious work-up was negative.
Autoimmune evaluation demonstrated anti-nuclear anti-
bodies (ANA) with elevated anti-double stranded DNA (477U
(range 0e29U)) as well as anti-smooth muscle antibody (SM
Ab e 77 U (0-19.9)). SLE diagnosis was made by Rheuma-
tology and the patient was started on hydroxy-chloroquine,
celecoxib and prednisone. The patient responded and is
currently on maintenance therapy. In retrospect, donor his-
tory was notable for chronic pain and labs showed a mild
eosinophilia with an absolute eosinophil count of 530/ml.
Signiﬁcantly, the donor was subsequently tested and diag-
nosed with SLE as well.
Donor screening for auto-immune diseases could be
considered in those with suspicious ﬁndings on evaluation.
This case demonstrates a real threat to recipient morbidity
after HCT due to a donor-related immune issue. Further
study is needed to understand the incidence, severity and
pattern of autoimmune diseases after HCT.AUTOLOGOUS TRANSPLANTS137
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Purpose: To review the outcomes of refractory and relapsed
Hodgkin’s Lymphoma in pediatric patients treated with high
dose chemotherapy (HDC) followed by autologous stem cell
transplantation (ASCT) at a single center.
Materials and Methods: All patients, up to the age of 18
years, with refractory or relapsed Hodgkin’s Lymphomawho
had complete or good-partial response to salvage chemo-
therapy were included in the study. All received HDC and
ASCT during October 2010 to June 2014. Medical records of
these patients were reviewed. The following variables were
collected in addition to demographics and stage of disease at
the time of relapse.
Time to engraftment from the day of stem cells re-
infusion
Radiological response assessed by PET-CT at day-60 after
stem cell re-infusion and
Disease free interval till the last follow-up
Results: Nineteen patients were studied, 15 were male.
Median age at relapse was 13 years (range 4-18 years). At the
time of relapse, 10 patients had stage IV disease, 6 had stage
III and two of stage II and one of Stage I. Median time to
engraftment was 13 days (range 10-21 days). Complete
metabolic remissionwas demonstrated in all 19 cases on FDG
PET/CT scan on day-60. Two patients had signiﬁcant
morphological residual disease requiring involved ﬁeld ra-
diation therapy. All but one patient remained disease free for
the duration of follow-up (median 16 months, range 3- >44
months). Disease free survival (DFS) was 92% during this
follow-up period. One patient had disease progression at 7
months post ASCT.
Conclusion: HDC(BEAM) followed by ASCT appears an
effective treatment strategy for relapsed or refractory pedi-
atric Hodgkin’s Lymphoma who had complete or good-par-
tial response to salvage chemotherapy, in our single center
experience during our short term follow-up. Long term
follow-up is suggested to evaluate disease free and overall
survival beneﬁts.
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Background: High-dose melphalan followed by autologous
stem cell rescue has been shown to signiﬁcantly increase
progression free survival and overall survival in patients with
multiple myeloma. Renal failure (RF) often precludes patient
enrollment in studies involving high-dose mephalan condi-
tioning for autologous stem cell transplant (ASCT) due to
increased treatment-related morbidity and mortality. How-
ever, several studies have shown that RF should not be an
exclusion criterion and early ASCT could be helpful in
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tioning regimen has yet to be determined as data is limited.
Also, most of these studies have used a one-day washout
formelphalan prior to stem cell infusion.
Patients and Methods: We conducted a retrospective study
of 17 patients with multiple myeloma on hemodialysis who
underwent ASCT over a period of 8 years at a single institu-
tion. All patients underwent ASCT with the same condi-
tioning regimen that consisted of melphalan 70mg/m2 days
-4 and -3, for a total of melphalan 140mg/m2, followed by a
two-day washout period on days -2 and day -1 with stem cell
infusion on day 0. Patients underwent hemodialysis on day
-4 prior to the ﬁrst dose of melphalan, day -2 (24 hours after
2nd dose of melphalan is given), and again on day 0. A two-
day washout was used to allow a longer duration for
melphalan to clear prior to stem cell infusion. OS was
calculated from day of transplant to date of death or last
follow up.
Results: A total of 17 patients on hemodialysis with multiple
myeloma underwent ASCT between April 2006 and May
2014 with high-dose melphalan and two-day washout. The
median number of therapies prior to transplant was 1.5
(range, 1-3) with only 4 (24%) of patients VGPR at the time
of transplant. There were 6 (35%) patients with grade III
toxicity (majority were mucositis) and no grade IV toxicities
reported. The median time to engraftment was 11 days
(range, 10-16) and the best response post-ASCT by 1year
evaluation included the following: 11 (65%) patients with CR,
2 (7%) VGPR, 3 PR (18%), 1 (6%) patient with stable disease,
and 1 patient was inevaluable because of death before 1 year
post-ASCT response assessment. There were no deaths
within the 100 days of ASCT; however one patient died of
septic shock before 1 year post-ASCT response assessment.
At a median follow up of 2.7 years, the overall survival wasFigure 1. Overall survival.
Figure 2. Time to progression.w6.5 years (Figure 1) and time to progression w5 years
(Figure 2).
Conclusions: This is a single institution retrospective study
demonstrating that high-dose melphalan with a two-day
washout in patients with multiple myeloma on hemodialysis
is a safe regimenwith a lower toxicity, reducedmortality and
deep remissions. Future prospective studies are needed to
conﬁrm the reduced toxicity and continued beneﬁt of this
approach.139
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Background: High-dose chemotherapy and autologous pe-
ripheral blood stem cell (PBSC) transplantation is considered
a standard of care procedure for multiple hematological
malignances. Patients undergoing this procedure might face
multiple morbidities including mucosal inﬂammation and
neutropenic fever; both related to neutropenia. Based on our
pre-clinical work in an umbilical cord blood (UCB) trans-
plantation murine model, we found that hyperbaric oxygen
(HBO) improved UCB CD34+ cell engraftment. As a result, we
are currently conducting a pilot study exploring HBO in
clinical autologous PBSC transplantation. Our primary aim is
to determine the safety of HBO in this setting and secondarily
to determine its efﬁcacy in reducing time to neutrophil and
platelet engraftment compared to matched historic controls.
Materials/Methods: Patients with multiple myeloma (MM),
non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD)
that require autologous PBSC transplantation were included.
On day 0, patients received HBO treatment consisting of
exposure to 2.5 atmosphere absolutes for a total of 2 hours, in
a monoplace hyperbaric chamber, breathing 100% oxygen.
Six hours from the start of HBO, PBSC units were infused and
patients were followed daily for toxicity and blood count
recovery. A matched historic cohort was chosen based on
gender, age, conditioning regimen, and disease type.
Results: 16 patients were screened for this study, 13 were
enrolled, and 11 were treated. One patient did not get treated
because of an emergency use of the HBO chamber by another
patient. The main reasons for non-enrollment were insur-
ance denial, patient choice, and failure to meet study criteria.
The treated subjects were 6 males and 5 females with me-
dian age of 63 (range: 25-67) who had MM (n¼7), or NHL
(n¼4). For MM patients, the preparative regimen was high-
dose melphalan and for NHL patients it was BEAM or BEAC.
The median cell dose infused was 3.7 (2.52-6.11) X106 CD34/
Kg recipient body weight. Only one patient was unable to
